18F-fluoromisonidazole positron emission tomography may differentiate glioblastoma multiforme from less malignant gliomas

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 39, Issue 5, 2012, Pages 760-770

  Hirata, Kenji ^a   Terasaka, Shunsuke ^a   Shiga, Tohru ^a   Hattori, Naoya ^a   Magota, Keiichi ^b   Kobayashi, Hiroyuki ^a   Yamaguchi, Shigeru ^a   Houkin, Kiyohiro ^a   Tanaka, Shinya ^a   Kuge, Yuji ^c   Tamaki, Nagara ^a  

^a HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b HOKKAIDO UNIVERSITY HOSPITAL   (Japan)

^c HOKKAIDO UNIVERSITY   (Japan)

Author keywords

Fluorodeoxyglucose; Fluoromisonidazole; Glioblastoma multiforme; Hypoxia

Indexed keywords

1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL F 18; FLUORODEOXYGLUCOSE F 18; 1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL; DIAGNOSTIC AGENT; DRUG DERIVATIVE; MISONIDAZOLE;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; FEMALE; GLIOBLASTOMA; GRAY MATTER; HUMAN; MAJOR CLINICAL STUDY; MALE; POSITRON EMISSION TOMOGRAPHY; PROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; ANAPLASTIC CARCINOMA; BRAIN TUMOR; CANCER GRADING; CLINICAL TRIAL; DIFFERENTIAL DIAGNOSIS; GLIOMA; METABOLISM; MIDDLE AGED; PATHOLOGY; SCINTISCANNING; TRANSPORT AT THE CELLULAR LEVEL;

ADULT; AGED; ANAPLASIA; BIOLOGICAL TRANSPORT; BRAIN NEOPLASMS; DIAGNOSIS, DIFFERENTIAL; FEMALE; GLIOBLASTOMA; GLIOMA; HUMANS; MALE; MIDDLE AGED; MISONIDAZOLE; NEOPLASM GRADING; POSITRON-EMISSION TOMOGRAPHY;

EID: 84862587185     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-011-2037-0     Document Type: Article

References (41)

1. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007;114:97-109. doi:10.1007/s00401-007-0243-4.
2. Gorlia T, van den Bent MJ, Hegi ME, Mirimanoff RO, Weller M, Cairncross JG, et al. Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3. Lancet Oncol 2008;9:29-38. doi:10.1016/S1470-2045(07)70384-4.
3. Cho KH, Kim JY, Lee SH, Yoo H, Shin SH, Moon SH, et al. Simultaneous integrated boost intensity-modulated radiotherapy in patients with high-grade gliomas. Int J Radiat Oncol Biol Phys 2010;78:390-7. doi:10.1016/j.ijrobp.2009. 08.029.
4. Behin A, Hoang-Xuan K, Carpentier AF, Delattre JY. Primary brain tumours in adults. Lancet 2003;361:323-31. doi:10.1016/S0140-6736(03)12328-8.
5. Spetzler RF, Martin NA. A proposed grading system for arteriovenous malformations. J Neurosurg 1986;65:476-83. doi:10.3171/jns.1986.65.4.0476.
6. Sawaya R. Extent of resection in malignant gliomas: a critical summary. J Neurooncol 1999;42:303-5.
7. Stewart LA. Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 2002;359:1011-8.
8. Brasch R, Pham C, Shames D, Roberts T, van Dijke K, van Bruggen N, et al. Assessing tumor angiogenesis using macromolecular MR imaging contrast media. J Magn Reson Imaging 1997;7:68-74.
9. Law M, Oh S, Babb JS, Wang E, Inglese M, Zagzag D, et al. Lowgrade gliomas: dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging-prediction of patient clinical response. Radiology 2006;238:658-67. doi:10.1148/radiol.2382042180.
10. Cao Y, Nagesh V, Hamstra D, Tsien CI, Ross BD, Chenevert TL, et al. The extent and severity of vascular leakage as evidence of tumor aggressiveness in high-grade gliomas. Cancer Res 2006;66:8912-7. doi:10.1158/0008-5472.CAN-05- 4328.
11. Emblem KE, Nedregaard B, Nome T, Due-Tonnessen P, Hald JK, Scheie D, et al. Glioma grading by using histogram analysis of blood volume heterogeneity from MR-derived cerebral blood volume maps. Radiology 2008;247:808-17. doi:10.1148/radiol.2473070571.
12. Di Chiro G, DeLaPaz RL, Brooks RA, Sokoloff L, Kornblith PL, Smith BH, et al. Glucose utilization of cerebral gliomas measured by [18F] fluorodeoxyglucose and positron emission tomography. Neurology 1982;32:1323-9.
13. Kaschten B, Stevenaert A, Sadzot B, Deprez M, Degueldre C, Del Fiore G, et al. Preoperative evaluation of 54 gliomas by PET with fluorine-18- fluorodeoxyglucose and/or carbon-11-methionine. J Nucl Med 1998;39:778-85.
14. Padma MV, Said S, Jacobs M, Hwang DR, Dunigan K, Satter M, et al. Prediction of pathology and survival by FDG PET in gliomas. J Neurooncol 2003;64:227-37.
15. Borbély K, Nyáry I, Tóth M, Ericson K, Gulyás B. Optimization of semi-quantification in metabolic PET studies with 18Ffluorodeoxyglucose and 11C-methionine in the determination of malignancy of gliomas. J Neurol Sci 2006;246:85-94. doi:10.1016/j.jns.2006.02.015.
16. Oliver L, Olivier C, Marhuenda FB, Campone M, Vallette FM. Hypoxia and the malignant glioma microenvironment: regulation and implications for therapy. Curr Mol Pharmacol 2009;2:263-84.
17. Flynn JR, Wang L, Gillespie DL, Stoddard GJ, Reid JK, Owens J, et al. Hypoxia-regulated protein expression, patient characteristics, and preoperative imaging as predictors of survival in adults with glioblastoma multiforme. Cancer 2008;113:1032-42. doi:10.1002/cncr.23678.
18. Evans SM, Judy KD, Dunphy I, Jenkins WT, Hwang WT, Nelson PT, et al. Hypoxia is important in the biology and aggression of human glial brain tumors. Clin Cancer Res 2004;10:8177-84. doi:10.1158/1078-0432.CCR-04-1081.
19. Lally BE, Rockwell S, Fischer DB, Collingridge DR, Piepmeier JM, Knisely JP. The interactions of polarographic measurements of oxygen tension and histological grade in human glioma. Cancer J 2006;12:461-6.
20. Rasey JS, Grunbaum Z, Magee S, Nelson NJ, Olive PL, Durand RE, et al. Characterization of radiolabeled fluoromisonidazole as a probe for hypoxic cells. Radiat Res 1987;111:292-304.
21. Martin GV, Caldwell JH, Rasey JS, Grunbaum Z, Cerqueira M, Krohn KA. Enhanced binding of the hypoxic cell marker [3H] fluoromisonidazole in ischemic myocardium. J Nucl Med 1989;30:194-201.
22. Rasey JS, Koh WJ, Grierson JR, Grunbaum Z, Krohn KA. Radiolabelled fluoromisonidazole as an imaging agent for tumor hypoxia. Int J Radiat Oncol Biol Phys 1989;17:985-91.
23. Valk PE, Mathis CA, Prados MD, Gilbert JC, Budinger TF. Hypoxia in human gliomas: demonstration by PET with fluorine-18- fluoromisonidazole. J Nucl Med 1992;33:2133-7.
24. Rajendran JG, Mankoff DA, O'Sullivan F, Peterson LM, Schwartz DL, Conrad EU, et al. Hypoxia and glucose metabolism in malignant tumors: evaluation by [18F]fluoromisonidazole and [18F] fluorodeoxyglucose positron emission tomography imaging. Clin Cancer Res 2004;10:2245-52.
25. Bruehlmeier M, Roelcke U, Schubiger PA, Ametamey SM. Assessment of hypoxia and perfusion in human brain tumors using PET with 18F- fluoromisonidazole and 15O-H2O. J Nucl Med 2004;45:1851-9.
26. Cher LM, Murone C, Lawrentschuk N, Ramdave S, Papenfuss A, Hannah A, et al. Correlation of hypoxic cell fraction and angiogenesis with glucose metabolic rate in gliomas using 18Ffluoromisonidazole, 18F-FDG PET, and immunohistochemical studies. J Nucl Med 2006;47:410-8.
27. Spence AM, Muzi M, Swanson KR, O'Sullivan F, Rockhill JK, Rajendran JG, et al. Regional hypoxia in glioblastoma multiforme quantified with [18F]fluoromisonidazole positron emission tomography before radiotherapy: correlation with time to progression and survival. Clin Cancer Res 2008;14:2623-30. doi:10.1158/1078-0432.CCR-07-4995.
28. Swanson KR, Chakraborty G, Wang CH, Rockne R, Harpold HL, Muzi M, et al. Complementary but distinct roles for MRI and 18Ffluoromisonidazole PET in the assessment of human glioblastomas. J Nucl Med 2009;50:36-44. doi:10.2967/jnumed.108.055467.
29. Szeto MD, Chakraborty G, Hadley J, Rockne R, Muzi M, Alvord Jr EC, et al. Quantitative metrics of net proliferation and invasion link biological aggressiveness assessed by MRI with hypoxia assessed by FMISO-PET in newly diagnosed glioblastomas. Cancer Res 2009;69:4502-9. doi:10.1158/0008-5472.CAN- 08-3884.
30. Kawai N,Maeda Y, Kudomi N,Miyake K, Okada M, Yamamoto Y, et al. Correlation of biological aggressiveness assessed by 11Cmethionine PET and hypoxic burden assessed by 18Ffluoromisonidazole PET in newly diagnosed glioblastoma. Eur J Nucl MedMol Imaging 2011;38:441-50. doi:10.1007/s00259-010- 1645-4.
31. Oh SJ, Chi DY, Mosdzianowski C, Kim JY, Gil HS, Kang SH, et al. Fully automated synthesis of [18F]fluoromisonidazole using a conventional [18F]FDG module. Nucl Med Biol 2005;32:899-905. doi:10.1016/j.nucmedbio.2005.06.003.
32. Tang G, Wang M, Tang X, Gan M, Luo L. Fully automated onepot synthesis of [18F]fluoromisonidazole. Nucl Med Biol 2005;32:553-8. doi:10.1016/j.nucmedbio. 2005.03.010.
33. Minoshima S, Frey KA, Koeppe RA, Foster NL, Kuhl DE. A diagnostic approach in Alzheimer's disease using three-dimensional stereotactic surface projections of fluorine-18-FDG PET. J Nucl Med 1995;36:1238-48.
34. Minoshima S, Koeppe RA, Frey KA, Kuhl DE. Anatomic standardization: linear scaling and nonlinear warping of functional brain images. J Nucl Med 1994;35:1528-37.
35. Kracht LW, Miletic H, Busch S, Jacobs AH, Voges J, Hoevels M, et al. Delineation of brain tumor extent with [11C]L-methionine positron emission tomography: local comparison with stereotactic histopathology. Clin Cancer Res 2004;10:7163-70. doi:10.1158/ 1078-0432.CCR-04-0262.
36. Galldiks N, Ullrich R, Schroeter M, Fink GR, Jacobs AH, Kracht LW. Volumetry of [(11)C]-methionine PET uptake and MRI contrast enhancement in patients with recurrent glioblastoma multiforme. Eur J Nucl Med Mol Imaging 2010;37:84-92. doi:10.1007/ s00259-009-1219-5.
37. Lee ST, Scott AM. Hypoxia positron emission tomography imaging with 18f-fluoromisonidazole. Semin Nucl Med 2007;37:451-61. doi:10.1053/j.semnuclmed. 2007.07.001.
38. Collingridge DR, Piepmeier JM, Rockwell S, Knisely JP. Polarographic measurements of oxygen tension in human glioma and surrounding peritumoural brain tissue. Radiother Oncol 1999;53:127-31.
39. Koch CJ, Evans SM. Non-invasive PET and SPECT imaging of tissue hypoxia using isotopically labeled 2-nitroimidazoles. Adv Exp Med Biol 2003;510:285-92.
40. Rasey JS, Nelson NJ, Chin L, Evans ML, Grunbaum Z. Characteristics of the binding of labeled fluoromisonidazole in cells in vitro. Radiat Res 1990;122:301-8.
41. Thorwarth D, Eschmann SM, Paulsen F, Alber M. A kinetic model for dynamic [18F]-Fmiso PET data to analyse tumour hypoxia. Phys Med Biol 2005;50:2209-24. doi:10.1088/0031-9155/50/10/ 002.